Stock Price Quote

NURECA LTD.

NSE : NURECABSE : 543264ISIN CODE : INE0DSF01015Industry : Medical Equipment/Supplies/AccessoriesHouse : Private
BSE281.75-5.1 (-1.78 %)
PREV CLOSE ( ) 286.85
OPEN PRICE ( ) 281.35
BID PRICE (QTY) 281.25 (9)
OFFER PRICE (QTY) 285.45 (18)
VOLUME 503
TODAY'S LOW / HIGH ( )276.25 282.85
52 WK LOW / HIGH ( )198 343.6
NSE281.550.1 (+0.04 %)
PREV CLOSE( ) 281.45
OPEN PRICE ( ) 284.45
BID PRICE (QTY) 281.90 (4)
OFFER PRICE (QTY) 282.40 (4)
VOLUME 8989
TODAY'S LOW / HIGH( ) 276.55 284.55
52 WK LOW / HIGH ( )203.62 343
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-11 2016
Management Info
Saurabh Goyal - Chairman Saurabh Goyal - Managing Director
Registered Office

Address B-205, Bldg - 42, B Wing,Dhanashree Heights, Azad Nagar Sangam C H S,Andheri West,
Mumbai,
Maharashtra-400053

Phone 0172-5292900

Email cs@nureca.com

Website www.nureca.com

Registrars Details
Alankit Assignments Ltd.
205-208 , Anarkali Complex,Jhandewala Extension,,New Delhi
Listing : BSE, NSE

NEWS

01Jan Announcement under Regulation 30 (LOD
Nureca Limited has informed the exchange about the Post Buyback Public A..
16Dec Letter of Offer
Mefcom Capital Markets Ltd ("Manager to the Buyback") has submitted to B..
02Dec Announcement under Regulation 30 (LOD
Nureca Limited has informed the Stock Exchange about the Public Announce..
28Nov Corporate Action- Fixes Record Date F
Nureca Limited has informed the Exchange regarding Record Date for Buyba..
24Jul Nureca informs about filing of scheme
Nureca has informed that in furtherance to communication dated May 20, 2..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit32.31-6.68000000000007
Gross Profit 40.48 -4.60000000000007
Operating Profit 46.828.0799999999999
Net Sales 396.41146.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

3B Blackbio Dx (BSE)
peergroup  1616.70 (1.45%)
M.Cap ( in Cr)1364.64
Poly Medicure (BSE)
peergroup  1299.00 (0.78%)
M.Cap ( in Cr)13146.33
Transpact Enterprise (BSE)
peergroup  158.70 (4.93%)
M.Cap ( in Cr)5.85
Prevest Denpro (BSE)
peergroup  455.00 (1.02%)
M.Cap ( in Cr)540.62
GKB Ophthalmics (BSE)
peergroup  62.00 (1.36%)
M.Cap ( in Cr)31.35

Shareholding Pattern

PROMOTERS 68.09%
NON-INSTITUTION 31.83%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Nureca Ltd.

Nureca Ltd. was incorporated in the year 2016. Its today's share price is 281.75. Its current market capitalisation stands at Rs 267.75 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1269.68 Cr and Total Income of Rs.1274.5 Cr. The company's management includes Rajinder Sharma, Nishu Kansal, Rupinder Tewari, Kuldip Kumar Bhasin, Ruchita Agarwal, Charu Singh, Vijay Kumar Sharma, Saurabh Goyal, Saurabh Goyal, Aryan Goyal.

It is listed on the BSE with a BSE Code of 543264 , NSE with an NSE Symbol of NURECA and ISIN of INE0DSF01015. It's Registered office is at B-205, Bldg - 42, B Wing,Dhanashree Heights, Azad Nagar Sangam C H S,Andheri WestMumbai-400053, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.